Combination therapy with erlotinib and TGF-β type I receptor inhibitors effectively inhibited metastasis in erlotinib-resistant NSCLC cells.268 However, it is worth noting that dual inhibition of EGFR and TGFβR did not completely prevent acquired gefitinib resistance. This evidence concerns the gene EGFR and non-small cell lung carcinoma.